Last reviewed · How we verify
Ecolid (CHLORISONDAMINE)
Ecolid (generic name: CHLORISONDAMINE) is a drug. It is currently in Phase 2 development.
Ecolid works by binding to specific proteins or receptors in the body to produce a therapeutic effect.
Ecolid, also known as Chlorisondamine, is a small molecule drug with unknown target and drug class. Its commercial status is unclear, and it has not been approved by the FDA for any indications. As a small molecule, it is likely to work by interacting with specific biological molecules to produce a therapeutic effect. However, without more information, it is difficult to provide a comprehensive summary of its mechanism of action and safety considerations. Further research is needed to fully understand this compound.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | CHLORISONDAMINE |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells are like locks, and Ecolid is a key that fits into those locks. When it binds to the right lock, it can turn on or off certain cellular processes to help treat a disease or condition. This is a simplified way of describing how small molecules like Ecolid work to produce their effects.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ecolid CI brief — competitive landscape report
- Ecolid updates RSS · CI watch RSS
Frequently asked questions about Ecolid
What is Ecolid?
How does Ecolid work?
What is the generic name of Ecolid?
What development phase is Ecolid in?
Related
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing